Yahoo! Finance Search - Finance Home - Yahoo! - Help
GlobeNewswire

Press ReleaseSource: HeartWare International, Inc.

HeartWare to Report 2009 Third Quarter and Nine Month Financial Results
Wednesday October 28, 6:05 pm ET

FRAMINGHAM, Mass. and SYDNEY, Australia, Oct. 28, 2009 (GLOBE NEWSWIRE) -- HeartWare International, Inc. (Nasdaq:HTWR - News) (ASX:HIN - News) will release financial results for the third quarter and nine months ended September 30, 2009 after the U.S. markets close on Wednesday, November 4, 2009.

A conference call with management is scheduled for 8:00 am U.S. Eastern Standard Time on Thursday, November 5, 2009 (being 12:00 am Australian Eastern Daylight Time between November 5 and 6, 2009) to discuss the Company's financial results and to provide a corporate update. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial +1-201-689-8471.

A live web cast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter and Nine Months Conference Call" under the section titled "Corporate Presentations" on the HOME page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized, implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare(R) Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a bridge-to-transplant indication.

HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.


Contact:
Allen & Caron Inc
U.S. Investor Relations 
Matt Clawson, Partner
matt@allencaron.com
+1 949 474 4300

Source: HeartWare International, Inc.


Mail to Friend Email Story
Alerts Set News Alert
Printer
Version  Print Story